Sort
30,917 grants matching “tumor microenvironment”
Impact of pre-existing T cell memory on oncolytic virus therapy
$262,400Pamela Rosato · Dartmouth College · P20 · FY2022 · GM
Stromal senescence in lethal prostate cancer: a novel target for prognosis and therapy
$262,383Elizabeth A. Platz · Johns Hopkins University · R01 · FY2025 · CA
Mechanisms of Sensitivity and Resistance to the Kinase Inhibitor Cabozantinib in Castrate Resistant Prostate Cancer
$262,312Evan Todd Keller · University Of Michigan At Ann Arbor · P50 · FY2018 · CA
Selective histone deacetylase inhibition with entinostat to enhance the anti-tumor immune response to immune checkpoint inhibition in urothelial cancer
$262,296Tracy L Rose · Univ Of North Carolina Chapel Hill · K08 · FY2021 · CA
Selective histone deacetylase inhibition with entinostat to enhance the anti-tumor immune response to immune checkpoint inhibition in urothelial cancer
$262,296Tracy L Rose · Univ Of North Carolina Chapel Hill · K08 · FY2022 · CA
Selective histone deacetylase inhibition with entinostat to enhance the anti-tumor immune response to immune checkpoint inhibition in urothelial cancer
$262,296Tracy L Rose · Univ Of North Carolina Chapel Hill · K08 · FY2020 · CA
IMMUNOTHERAPY WITH CAR T CELLS
$262,288Carl H. June · University Of Pennsylvania · R01 · FY2014 · CA
Building clinically faithful ex vivo indolent lymphoma models for personalized therapy
$262,268Y. Lynn Wang · Research Inst Of Fox Chase Can Ctr · R21 · FY2021 · CA
Non-invasive characterization of human soft tissue sarcoma response to radiation therapy
$262,249Everett James Moding · Stanford University · K08 · FY2025 · CA
Non-invasive characterization of human soft tissue sarcoma response to radiation therapy
$262,249Everett James Moding · Stanford University · K08 · FY2024 · CA
Non-invasive characterization of human soft tissue sarcoma response to radiation therapy
$262,249Everett James Moding · Stanford University · K08 · FY2023 · CA
Non-invasive characterization of human soft tissue sarcoma response to radiation therapy
$262,249Everett James Moding · Stanford University · K08 · FY2022 · CA
Cell Processing and Immune Assessment
$262,216Jerome Ritz · Dana-Farber Cancer Inst · P01 · FY2014 · CA
Role of the UPR in myc-induced tumorigenesis
$262,116Constantinos Koumenis · University Of Pennsylvania · P01 · FY2016 · CA
Defining the role of KEAP/NRF2 signaling dysregulation and sensory nerve reprograming during acquisition of cisplatin resistance and metastasis in HNSCC
$262,103Abdullah Ali Osman · University Of Tx Md Anderson Can Ctr · U54 · FY2024 · CA
Mitosis in Confining Microenvironments
$262,071Taeyoon Kim · Purdue University · R01 · FY2023 · GM
Project 3: Inter-Relationships and Prognostic Significance of Breast Cancer Radiomic Risk Features, Tissue Microenvironment, and Adiposity
$262,001John Alan Shepherd · University Of Hawaii At Manoa · P20 · FY2025 · CA
Evolutionary dynamics of non-genetic mechanisms of drug resistance in cancer
$262,000Jasmine Y Foo · University Of Minnesota-Twin Cities · · FY2021 · MPS
The therapeutic potential of maspin in prostate cancer
$261,975Shijie Sheng · Wayne State University · R01 · FY2009 · CA
The therapeutic potential of maspin in prostate cancer
$261,975Shijie Sheng · Wayne State University · R01 · FY2008 · CA
The therapeutic potential of maspin in prostate cancer
$261,975Shijie Sheng · Wayne State University · R01 · FY2010 · CA
Antitumor Mechanisms of anti-CD40/CpG-activated Macrophages
$261,901Paul M Sondel · University Of Wisconsin-Madison · R01 · FY2012 · CA
Antitumor Mechanisms of anti-CD40/CpG-activated Macrophages
$261,901Paul M Sondel · University Of Wisconsin-Madison · R01 · FY2011 · CA
Core 1: Tissue Microfabrication Core
$261,893Jeffrey David Varner · Cornell University · U54 · FY2019 · CA
Prostate Oncology
$261,841Max S. Wicha · University Of Michigan At Ann Arbor · P30 · FY2014 · CA